MinalAtulBarveMD(She/Her)

[Pronunciation: mee-nul, bar-vay ]

Oncology • Dallas, TX

Physician

Join to view full profile

Dr. Barve is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Barve's full profile

Already have an account?

Office
8196 Walnut Hill Ln
Ste 100
Dallas, TX 75231
Phone+1 214-739-4175

Fax+1 214-987-4161

Education & Training

Baylor University Medical CenterFellowship, Hematology and Medical Oncology, 2001 - 2003
Texas Health Resources (Dallas)Residency, Internal Medicine, 1996 - 1999
Dr P Deshmukh Mem Medicine Coll, Amravati UniversityClass of 1993

Certifications & Licensure

TX State Medical License 2000 - 2026
CO State Medical License 1999 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Salvage Ovarian FANG™ Vaccine + Carboplatinum Start of enrollment: 2013 Jun 01
Completed
Phase 2
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma Start of enrollment: 2016 Feb 10
Completed
Phase 2
Pilot Study of Durvalumab and Vigil in Advanced Women's Cancers Start of enrollment: 2016 Jun 03
Completed
Phase 2
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies Start of enrollment: 2019 May 17
Recruiting
Phase 1
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Start of enrollment: 2021 Aug 03
Active, not recruiting
Phase 1
Roles: Contact
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS Start of enrollment: 2022 May 31
Recruiting
Phase 1
A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas Start of enrollment: 2022 Mar 28
Recruiting
Phase 1
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors Start of enrollment: 2022 Jun 20
Recruiting
Phase 1
TH1902 in Patients With Advanced Solid Tumors Start of enrollment: 2021 Mar 04
Recruiting
Phase 1
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers Start of enrollment: 2020 Sep 23
Recruiting
Phase 1
Study of GS-1811 Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors Start of enrollment: 2021 Aug 18
Recruiting
Phase 1
A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) Start of enrollment: 2021 Jun 22
Recruiting
Phase 1
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Start of enrollment: 2021 Jan 18
Recruiting
Phase 2
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation Start of enrollment: 2023 Dec 28
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Safety, Efficacy, and Pharmacokinetics of SHR-A1811, a Human Epidermal Growth Factor Receptor 2-Directed Antibody-Drug Conjugate, in Human Epidermal Growth Factor Rece...
Herui Yao, Min Yan, Zhongsheng Tong, Xinhong Wu, Min-Hee Ryu
Journal of Clinical Oncology. 2024-10-10
Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial.
Nirav N Shah, Michael Wang, Lindsey E Roeker, Krish Patel, Jennifer A Woyach
Haematologica. 2024-10-03
1 citations
Pharmacokinetic study of capivasertib and the CYP3A4 substrate midazolam in patients with advanced solid tumors.
Claire Miller, Roberto Sommavilla, Cindy L O'Bryant, Minal Barve, Afshin Dowlati
Cancer Chemotherapy and Pharmacology. 2024-08-01

Press Mentions

Drug Combinations and New Approvals Delivering Optimistic Results in Oncology StocksDecember 8th, 2021
Gradalis®, Inc. Announces Dosing of First Patient in Pilot Study Combining Vigil® Engineered Autologous Tumor Cell Immunotherapy and Durvalumab in Advanced Breast CancerAugust 29th, 2016